Novel ANG-2 antagonist peptides and methods of purification

Novel Ang-2 antagonist peptides and chimeric molecules with enhanced binding capabilities address the challenges of high dosage requirements, providing effective treatments for cancer and eye diseases by inhibiting VEGF and Ang-2 interactions, improving treatment efficacy and formulation stability.

WO2026241285A1PCT designated stage Publication Date: 2026-11-19ASKGENE PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027832
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current dual antagonists for VEGF and Ang-2 have challenges with high dosage requirements and formulation difficulties, necessitating the development of molecules with enhanced binding affinities to effectively treat conditions like cancer and eye diseases.

Method used

Development of novel Ang-2 antagonist peptides and chimeric molecules with improved binding capabilities, including specific amino acid sequences and structural modifications, which inhibit the interactions between VEGF and its receptor, and Ang-2 and its receptor, and are produced using recombinant methods and optimized purification processes.

Benefits of technology

The novel peptides and chimeric molecules demonstrate enhanced efficacy in inhibiting the biological activities of Ang-2 and VEGF, offering potential treatments for conditions such as cancer, proliferative retinopathy, and macular degeneration with reduced variability and improved formulation stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027832_19112026_PF_FP_ABST
    Figure US2026027832_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to novel Ang-2 antagonist peptide, and related chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of production, and methods of using said chimeric molecules to treat a patient with proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.: 143302-00520NOVEL ANG-2 ANTAGONIST PEPTIDES AND METHODS OF PURIFICATIONCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 805,092, filed on May 13, 2025. The entire contents of the foregoing application are expressly incorporated by reference herein.REFERENCE TO A SEQUENCE LISTING XML

[0002] This application contains a Sequence Listing which has been submitted electronically in XML format. The Sequence Listing XML is incorporated herein by reference. Said XML file, created on May 8, 2026, is named 143302-00520_SL.xml and is 44,840 bytes in size.FIELD OF THE INVENTION

[0003] The present application relates to novel Ang-2 antagonist peptides and chimeric molecules which bind to both VEGF and Ang-2 and inhibit the interaction between VEGF and its receptor and the interaction between Ang-2 and its receptor. Methods of purification and methods of use of said chimeric molecules are also presented.BACKGROUND OF THE INVENTION

[0004] Angiogenesis is implicated in the pathogenesis of a variety of disorders including solid tumors, intraocular neovascular syndromes such as proliferative retinopathies or age-related macular degeneration (AMD), rheumatoid arthritis, and psoriasis (see, e.g., Folkman, J., et al., J. Biol. Chem. 267 (1992) 10931-10934; Klagsbrun, M., et al, Annu. Rev. Physiol. 53 (1991) 217-239; and Garner, A., Vascular Diseases, in: Pathobiology of Ocular Disease, A Dynamic Approach, Garner, A., and Klintworth, G. K. (eds.), 2nd edition, Marcel Dekker, New York (1994), pp. 1625- 1710). In the case of solid tumors, the neovascularization allows the tumor cells to acquire a growth advantage and proliferative autonomy compared to the normal cells. Accordingly, a correlation has been observed between density of microvessels in tumor sections and patient survival in a number of cancers (see, e.g., Weidner, N., et al, N Engl J Med. 324 (1991) 1-8; Horak, E.R., et al, Lancet 340 (1992) 1120-1124; and Macchiarini, P„ et al, Lancet 340 (1992) 145-146).1MEl\60901856.vlAttorney Docket No.: 143302-00520

[0005] Human vascular endothelial growth factor (VEGF / VEGF-A) is described in, e.g., Leung, D.W., et al, Science 246 (1989) 1306-9; Keck, P.J., et al, Science 246 (1989) 1309-12 and Connolly, D.T., et al, J. Biol. Chem. 264 (1989) 20017-24. The expression of VEGF is potentiated in response to hypoxia, by activated oncogenes, and by a variety of cytokines. VEGF is involved in the regulation of normal and abnormal angiogenesis and neovascularization associated with tumors and intraocular disorders (Ferrara, N., et al, Endocr. Rev. 18 (1997) 4-25; Berkman, R.A., et al, J. Clin. Invest. 91 (1993) 153-159; Brown, L.F., et al, Human Pathol. 26 (1995) 86- 91 ; Brown, L.F., et al, Cancer Res. 53 (1993) 4727-4735; Mattern, J., et al, Brit. J. Cancer. 73 (1996) 931-934; and Dvorak, H.F., et al, Am. J. Pathol. 146 (1995) 1029-1039).

[0006] Deregulated VEGF expression contributes to the development of solid tumors by promoting tumor angiogenesis and to the etiology of several additional diseases that are characterized by abnormal angiogenesis (Kim, K. J., et al., 1993. Nature (London) 362, 841-844; Millauer, B., et al., 1994. Nature (London) 367, 576-579). Consequently, inhibition of VEGF signaling abrogates the development of a wide variety of tumors.

[0007] In retinopathies, in which partial or general ischemia of the retina is accompanied by overexpression of VEGF and hyperproliferation of blood vessels, blindness can result (Aiello, L. P et al., 1994. N. Engl. J. Med. 331 , 1480-1487;Adamis, A. P., et al., Am. J. Ophthalmol. 118, 445-450). Inhibition of VEGF expression in such disease states can treat or prevent resulting blindness.

[0008] Human angiopoietin-2 (ANG-2 or Ang-2 or Ang2) (alternatively abbreviated with ANGPT2 or ANG2) is described in Maisonpierre, P.C., et al, Science 277 (1997) 55-60 and Cheung, A.H., et al, Genomics 48 (1998) 389-91. Ang2 plays an important role in angiogenesis and its expression levels have been correlated with cancer and eye diseases (Gerald D et al., Cancer Res. 2013, 73(6) :1649-57; Watanabe et al., Am J Ophthalmol. 2005, 139(3):476-81).

[0009] Dual antagonist RG7716 demonstrated superior efficacy than VEGF antagonist ranibizumab in a recent clinical trial. However, the reported dosage for RG7716 at 6 mg per dose was rather high considering the volume of administration2MEl\60901856.vlAttorney Docket No.: 143302-00520to eye is typically low, e.g. 50 micoL). This could require a concentration of 120 mg / ml, a significant challenge for formulation development. A dual antagonist with stronger binding affinities to VEGF and / or Ang2 is needed. The present invention includes dual antagonist molecules with enhanced binding ability and which result in a reduction in the severity of a disease in a patient treated with a molecule disclosed herein.SUMMARY OF THE INVENTION

[0010] The present disclosure relates to novel Ang-2 antagonist peptides, and chimeric molecules comprising said Ang-2 antagonist. Further disclosed are methods of making said chimeric molecules, the pharmaceutical composition of said chimeric molecules, and methods to treat a patient of cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

[0011] A chimeric molecule named “03” comprises two identical light chains of SEQ ID NO: 26 and two identical heavy chain-peptide fusion polypeptides of SEQ ID NO: 31. When 03 was expressed by a CHO cell line and purified, it was discovered that it comprises multiple charge variants as analyzed by an ion exchange HPLC method (Figure 1 ). Further analysis by mass spectroscopy showed that the Ang-2 antagonist peptide moiety of the chimeric molecule 03 was clipped from the C-terminus and several variants of the chimeric molecule were formed. The genes of two variants of the chimeric molecules named O3 / QFM and 03 / QF were synthesized, wherein O3 / QFM comprises the Ang-2 antagonist peptide of SEQ ID NO: 5 and wherein 03 / QF comprises the Ang-2 antagonist peptide of SEQ ID NO: 6. Both molecules were expressed recombinantly and purified. Surprisingly, both O3 / QFM and 03 / QF were active in inhibiting the binding of Ang-2 to its receptor Tie-2 (Fig. 2), even though the Ang-2 antagonist peptides in O3 / QFM with 20 amino acids and 03 / QF with 19 amino acids were substantially shorter than the Ang-2 antagonist peptide in 03 (26 amino acids). Chimeric molecules such as O3 / QFM and 03 / QF have higher homogeneity and reduced variability when produced.

[0012] In some aspect, it is disclosed here novel Ang-2 antagonist peptides which comprises an amino acid sequence selected from SEQ ID NOs: 1-18; wherein said 3MEl\60901856.vlAttorney Docket No.: 143302-00520antagonist peptide binds to Ang-2 and inhibits a biological activity of Ang-2. In some embodiments, said antagonist peptide comprises one point mutation, a deletion of one amino acid, or an addition of one amino acid.

[0013] In some aspects, it is disclosed here chimeric molecules which comprises said antagonist peptide and an antigen-binding moiety, wherein said antigen-binding moiety binds to VEGF, IL-6, IL-1 a, C3, C5, or MASP2. In some aspect, said chimeric molecule which comprises said antagonist peptide and an antigen-binding moiety, wherein said antigen-binding moiety binds to a component and inhibits a biological activity of a signaling pathway selected from the VEGF signaling pathway, the IL-1 signaling pathway, the IL-6 signaling pathway, and the complement pathway.

[0014] In some embodiments, said chimeric molecule comprises an antagonist peptide with an amino acid sequence selected from SEQ ID NO: 1 , 4, 6, 10, 13, or 15, and an antigen-binding moiety; wherein said antigen-binding moiety binds to VEGF. In some embodiments, said VEGF-binding moiety comprises the same light chain and heavy chain CDR domains as that of Bevacizumab, ranibizumab, or brolucizumab. In some embodiments, said VEGF-binding moiety comprises a light chain variable domain of amino acid sequence of SEQ ID NO: 19 and a heavy chain variable domain of amino acid sequence of ID NO: 20.

[0015] In some embodiments, said chimeric molecule comprises said Ang-2 antagonist peptide, and an antibody or antigen-binding fragment thereof; wherein said chimeric molecule optionally comprises a first light chain, a second light chain, a first heavy chain-peptide fusion polypeptide chain, and a second heavy chain-peptide fusion polypeptide chain; wherein said peptide is an Ang-2 antagonist of any one of the preceding embodiments; and wherein said first and second light chains comprises an amino acid sequence of SEQ ID NO: 26, and said first and second heavy chain-peptide fusion polypeptides comprises an amino acid sequence selected from SEQ ID Nos: 28-36.

[0016] In some embodiments, said VEGF-binding moiety comprises the extracellular domain of a VEGF receptor or a fragment thereof. In some embodiments, said VEGF Trap comprises an amino acid sequence of SEQ ID NO: 21. In some embodiments,4MEl\60901856.vlAttorney Docket No.: 143302-00520said chimeric molecule comprises an amino acid sequence selected from SEQ ID NOs: 22-25.

[0017] In some aspects, provided herein is an antagonist peptide which binds to Ang-2 and inhibits a biological activity of Ang-2, comprising, consisting essentially of, or consisting of an amino acid sequence selected from any one of SEQ ID NOs: 1-18, such as any one of SEQ ID NOs: 2-4, 7-9, and 11-18.

[0018] In some aspects, provided herein is a chimeric molecule comprising the Ang-2 antagonist peptide of any one of the preceding embodiments, and an anti-vascular endothelial growth factor (VEGF) antibody or antigen-binding fragment thereof. In some embodiments, the anti-VEGF antibody or antigen-binding fragment thereof comprises two identical light chains each comprising the amino acid sequence of SEQ ID NO: 26 and two identical heavy chains each comprising the amino acid sequence of SEQ ID NO: 40. In some embodiments, the Ang-2 antagonist peptide is linked to the C-terminus of one of the heavy chains via an amino acid linker. In some embodiments, the chimeric molecule comprises a second Ang-2 antagonist peptide linked to the C-terminus of the other heavy chain via an amino acid linker, and wherein the second Ang-2 antagonist peptide comprises an amino acid sequence selected from any one of SEQ ID NOs: 2-4, 7-9, and 11-18.

[0019] In some aspects, provided herein is a chimeric molecule comprising the Ang-2 antagonist peptide of any one of the preceding embodiments, and a VEGF Trap; optionally wherein said VEGF Trap comprises the amino acid sequence of SEQ ID NO: 21 ; and / or said Ang-2 antagonist peptide is linked to the C-terminus of the VEGF Trap via an amino acid linker.

[0020] In some aspects, provided herein is an isolated polynucleotide encoding the chimeric molecule of any one of any one of the preceding embodiments. In some aspects, provided herein is an expression vector comprising the polynucleotide of any one of the preceding embodiments. In some aspects, provided herein is a host cell transfected with the polynucleotide of the preceding embodiments or the expression vector of any one of the preceding embodiments.

[0021] In some aspects, provided herein is a method of making the chimeric molecule of any one of any one of the preceding embodiments, comprising culturing 5MEl\60901856.vlAttorney Docket No.: 143302-00520the host cell of any one of the preceding embodiments under conditions that allow expression of the chimeric molecule, and isolating the chimeric molecule.

[0022] In some aspects, provided herein is a method of purifying the chimeric molecule of any one of the preceding embodiments, where the method comprises an affinity chromatography as its first chromatography step, which is eluted with an acidic solution with a pH of 2.4 - 4.0; and wherein the product eluant is collected into a vessel which contains a pH neutralization solution with optional mixing.

[0023] In some aspects, provided herein is a method of purifying the chimeric molecule of any one of the preceding embodiments, where the method comprises an affinity chromatography as its first chromatography step, which is eluted with an acidic solution with a pH of 2.4 - 4.0; and wherein the pH of the product eluant is adjusted simultaneously or on-line during the elution with a pH neutralization solution.

[0024] In some aspects, provided herein is a method of purifying a chimeric molecule comprising an affinity chromatography, wherein the affinity chromatography is eluted with an acidic solution with a pH of 2.4 - 4.0; wherein the product eluant is collected into a container which contains a pH neutralization solution, or the pH of the product eluant is adjusted simultaneously on-line during the elution with a pH neutralization solution; and wherein the chimeric molecule comprises an Ang-2 antagonist peptide which comprises the amino acid sequence of SEQ ID NO: 39 or a functional analog thereof.

[0025] In some embodiments, the chimeric molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence having at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO: 26, and a heavy chain-peptide fusion polypeptide chain comprising the amino acid sequence of SEQ ID NO: 27 or 31 or an amino acid sequence having at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO: 27 or 31.

[0026] In some embodiments, the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 37 or 38 or an amino acid sequence having at least 90%6MEl\60901856.vlAttorney Docket No.: 143302-00520(e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO: 37 or 38.

[0027] In some embodiments, the affinity chromatography is a Protein L affinity chromatography; and wherein the solution used to elute the product from the affinity column (or Elution Buffer) has a pH of approximately 2.5, approximately 2.6, approximately 2.7, approximately 2. approximately 2.8, approximately 2.9, approximately 3.0, approximately 3.1, approximately 3.2, approximately 3.3, approximately 3.4, approximately 3.5, approximately 3.6, approximately 3.7, approximately 3.8, approximately 3.9, or approximately 4.0; and wherein the resulted affinity column elution pool (e.g., the product eluant mixed with the pH neutralization solution either on-line or in the collection container) has a pH of 4.5 to 8.5, a pH of 5.5 to 7.5, a pH of 5.5 to 6.5, or a pH of approximately 6.0.

[0028] In some embodiments, the affinity chromatography is a Protein L affinity chromatography, wherein the chromatography comprises a washing step after loading; and wherein said washing step using a solution comprising 0.4 - 2.0 M arginine, pH 7.0-8.5.

[0029] In some embodiments, the affinity chromatography is a Protein L affinity chromatography, wherein the chromatography comprises an elution step; and wherein the elution step uses an elution buffer comprising approximately 100 mM glycine with a pH of approximately 2.5, or a solution comprising approximately 50 mM citric acid with a pH of approximately 2.9.

[0030] In some embodiments, the pH neutralization solution comprises Tris, bis-tris, Histidine, citrate, or arginine at a concentration of 0.01 - 3.0 M.

[0031] In some embodiments, the product eluant is collected into a vessel which contains approximately 0.3 column volumes (CVs) of the neutralization solution; and wherein the neutralization solution comprises approximately 0.25 M Tris with a pH of approximately 8.5.

[0032] In some embodiments, the method further comprises a second, a third and an optional fourth chromatography steps, a low pH viral inactivation step, and additional7MEl\60901856.vlAttorney Docket No.: 143302-00520process steps; wherein the low pH viral inactivation step is carried out after the second chromatography step, or after the third chromatography step.

[0033] In some embodiments, the method comprises the following steps with optional filtration step or steps before and / or after each chromatography step:a) clarification of the cultured cell culture medium;b) an affinity chromatography step;c) a second chromatography step;d) a low pH viral inactivation step; wherein the pH of the elution pool of the second chromatography step is adjusted to a pH of approximately 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0, incubate for approximately 30-90 min or approximately 60 min, and then adjusted to a pH of 5.5 - 8.0; ande) additional process steps.

[0034] In some embodiments, the method comprises the following steps with optional filtration step or steps before and / or after each chromatography step:a) clarification of the cultured cell culture medium;b) an affinity chromatography step;c) a second chromatography step;d) a third chromatography step;e) a low pH viral inactivation step; wherein the pH of the elution pool of the third chromatography step is adjusted to a pH of approximately 3.6, incubate for approximately 60 min at room temperature, and is adjusted to a pH of 5.5 - 8.0; andf) additional process steps.

[0035] In some embodiments, the method comprises the following steps with optional filtration step or steps before and / or after each chromatography step:a) clarification of the cultured cell culture medium;b) a Protein L affinity chromatography step;c) an anion exchange chromatography step carried out in a flow-through mode; d) a cation exchange chromatography step;8MEl\60901856.vlAttorney Docket No.: 143302-00520e) a low pH viral inactivation step; wherein the pH of the elution pool of the cation exchange chromatography step is adjusted to a pH of approximately 3.6, incubate for approximately 60 min at room temperature, and is adjusted to a pH of 5.5 - 8.0 or optionally approximately 7.5; andf) additional process steps.

[0036] In some embodiments, the method further comprises a viral-inactivation step; wherein the viral-inactivation step is not a low-pH viral-inactivation step; and wherein the viral-inactivation step optionally uses an organic-solvent or UV to inactivate potential viral particles in a product pool.

[0037] In some aspects, provided herein is a pharmaceutical composition which comprises the chimeric molecule purified by the method of any one of any one of the preceding embodiments as its active ingredient, wherein the pharmaceutical composition is used to treat a patient with proliferative retinopathy, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

[0038] In some embodiments, the pharmaceutical composition further comprises a second active ingredient at a concentration of 0.5 mg / ml or higher, a concentration of 1.0 mg / ml or higher, or a concentration of 1.5 mg / ml or higher; wherein the second active ingredient comprises a chimeric molecule, which comprises two identical light chains and two identical heavy chain-peptide fusion polypeptide chains; and wherein said light chain comprises the amino acid sequence of SEQ ID NO: 26, and said heavy chain-peptide fusion polypeptide chain comprises an amino acid sequence selected from any one of SEQ ID NOs: 28, 29, 30, 32, 33, 34, 35, and 36.

[0039] In some embodiments, the pharmaceutical composition further comprises a second active ingredient at a concentration of 15.0 mg / ml or lower, concentration of 10.0 mg / ml or lower, or a concentration of 6.0 mg / ml or lower; wherein the second active ingredient comprises a chimeric molecule, which comprises two identical light chains and two identical heavy chain-peptide fusion polypeptide chains; and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 26, and the heavy chain-peptide fusion polypeptide chain comprises an amino acid sequence selected from any one of SEQ ID NOs: 28, 29, 30, 32, 33, 34, 35, and 36.9MEl\60901856.vlAttorney Docket No.: 143302-00520

[0040] In some embodiments, the pharmaceutical composition further comprises a second active ingredient at a concentration of 0.5 mg / ml or higher, a concentration of 1.0 mg / ml or higher, or a concentration of 1.5 mg / ml or higher; wherein the second active ingredient comprises a chimeric molecule, which comprises two identical polypeptide chains which comprise an amino acid sequence selected from any one of SEQ ID NOs: 22-25.

[0041] In some embodiments, the pharmaceutical composition further comprises a second active ingredient at a concentration of 15.0 mg / ml or lower, concentration of 10.0 mg / ml or lower, or a concentration of 6.0 mg / ml or lower; wherein the second active ingredient comprises a chimeric molecule, which comprises two identical polypeptide chains which comprise an amino acid sequence selected from any one of SEQ ID NOs: 22 - 25.Methods of purification / production

[0042] Also disclosed are polynucleotide or polynucleotides and expression vectors which encode the above said chimeric molecules. Also disclosed are methods of making the above said chimeric molecules.

[0043] In some aspect, disclosed is a method of purifying a chimeric molecule said above, comprising an affinity chromatography as its first chromatography step, wherein said affinity chromatography is eluted with an acidic solution with a pH of 2.4 - 4.0; wherein the product eluant is collected into a vessel which contains a pH neutralization solution with optional mixing, or the pH of the product eluant is adjusted simultaneously or on-line during the elution with a pH neutralization solution.

[0044] In some aspect, disclosed is a method of purifying a chimeric molecule comprising an affinity chromatography, wherein said affinity chromatography is eluted with an acidic solution with a pH of 2.4 - 4.0; wherein the product eluant is collected into a container which contains a pH neutralization solution, or the pH of the product eluant is adjusted simultaneously on-line during the elution with a pH neutralization solution; and wherein said chimeric molecule comprises an Ang-2 antagonist peptide which comprises an amino acid sequence of SEQ ID NO: 39 or a functional analog thereof.10MEl\60901856.vlAttorney Docket No.: 143302-00520

[0045] In some embodiments, said chimeric molecule comprises a light chain with an amino acid sequence of SEQ ID NO: 26 or at least 95% identical as that of SEQ ID NO: 26, and a heavy chain-peptide fusion polypeptide chain with an amino acid sequence of SEQ ID NO: 27 or 31 or at least 98% identical as that of SEQ ID NO: 27 or 31. In some embodiments, said chimeric molecule comprises an amino acid sequence of SEQ ID NO: 37 or 38 or at least 98% identical as that of SEQ ID NO: 37 or 38.

[0046] In some embodiments, said affinity chromatography is a Protein L affinity chromatography; and wherein the solution used to elute the product from the affinity column (or Elution Buffer) has a pH of approximately 2.5, approximately 2.6, approximately 2.7, approximately 2. approximately 2.8, approximately 2.9, approximately 3.0, approximately 3.1, approximately 3.2, approximately 3.3, approximately 3.4, approximately 3.5, approximately 3.6, approximately 3.7, approximately 3.8, approximately 3.9, or approximately 4.0; and wherein the resulted affinity column elution pool (i.e. the product eluant mixed with the pH neutralization solution either on-line or in the collection container) has a pH of 4.5 to 8.5, a pH of 5.5 to 7.5, a pH of 5.5 to 6.5, or a pH of approximately 6.0.

[0047] In some embodiments, said affinity chromatography is a Protein L affinity chromatography, wherein said chromatography comprises a washing step after loading; and wherein said washing step using a solution comprising 0.4 - 2.0 M arginine, pH 7.0-8.5.

[0048] In some embodiments, said affinity chromatography is a Protein L affinity chromatography, wherein said chromatography comprises an elution step; and wherein said elution step using an elution buffer comprising approximately 100 mM glycine with a pH of approximately 2.5, or a solution comprising approximately 50 mM citric acid with a pH of approximately 2.9.

[0049] In some embodiments, said pH neutralization solution comprises Tris, bis-tris, Histidine, citrate, or arginine at a concentration of 0.01 - 3.0 M.

[0050] In some embodiments, said product eluant is collected into a vessel which contains approximately 0.3 column volumes (CVs) of the neutralization solution; and11MEl\60901856.vlAttorney Docket No.: 143302-00520wherein said neutralization solution comprises approximately 0.25 M Tris with a pH of approximately 8.5.

[0051] In some embodiments, said method further comprises a second, a third and an optional fourth chromatography steps, a low pH viral inactivation step, and additional process steps; wherein said low pH viral inactivation step is carried out after the second chromatography step, or after the third chromatography step.

[0052] In some embodiments, said method comprises the following steps sequentially from a) to e) with optional filtration step or steps before and / or after each chromatography step:a) Clarification of the cultured cell culture medium;b) An affinity chromatography step;c) A second chromatography step;d) A low pH viral inactivation step; wherein the pH of the elution pool of the second chromatography step is adjusted to a pH of approximately 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0, incubate for approximately 30-90 min or approximately 60 min, and then adjusted to a pH of 5.5 - 8.0; and e) Additional process steps.

[0053] In some embodiments, said method comprises the following steps sequentially from a) to f) with optional filtration step or steps before and / or after each chromatography step:a) Clarification of the cultured cell culture medium;b) An affinity chromatography step;c) A second chromatography step;d) A third chromatography step;e) A low pH viral inactivation step; wherein the pH of the elution pool of the third chromatography step is adjusted to a pH of approximately 3.6, incubate for approximately 60 min at room temperature, and is adjusted to a pH of 5.5 - 8.0; andf) Additional process steps.12MEl\60901856.vlAttorney Docket No.: 143302-00520

[0054] In some embodiments, said method comprises the following steps sequentially from a) to f) with optional filtration step or steps before and / or after each chromatography step:a) Clarification of the cultured cell culture medium;b) A Protein L affinity chromatography step;c) An anion exchange chromatography step carried out in a flow-through mode; d) A cation exchange chromatography step;e) A low pH viral inactivation step; wherein the pH of the elution pool of the cation exchange chromatography step is adjusted to a pH of approximately 3.6, incubate for approximately 60 min at room temperature, and is adjusted to a pH of 5.5 - 8.0 or optionally approximately 7.5; andf) Additional process steps.

[0055] In some embodiments, said method further comprises a viral-inactivation step; wherein said viral-inactivation step is not a low-pH viral-inactivation step; and wherein said viral-inactivation step optionally uses an organic-solvent or LIV to inactivate potential viral particles in a product pool.

[0056] Also disclosed is a pharmaceutical composition, which comprises said chimeric molecule purified by any of the above-described methods as its active ingredient; wherein said pharmaceutical composition is used to treat a patient with proliferative retinopathy, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

[0057] In some embodiments, said pharmaceutical composition further comprises a second active ingredient at a concentration of 0.5 mg / ml or higher, a concentration of 1.0 mg / ml or higher, or a concentration of 1.5 mg / ml or higher; wherein said second active ingredient comprises a chimeric molecule, which comprises two identical light chains and two identical heavy chain-peptide fusion polypeptide chains; and wherein said light chain comprises an amino acid sequence of SEQ ID NO: 26, and said heavy chain-peptide fusion polypeptide chain comprises an amino acid sequence selected from SEQ ID NOs: 28, 29, 30, 32, 33, 34, 35, and 36.13MEl\60901856.vlAttorney Docket No.: 143302-00520

[0058] In some embodiments, said pharmaceutical composition further comprises a second active ingredient at a concentration of 15.0 mg / ml or lower, concentration of 10.0 mg / ml or lower, or a concentration of 6.0 mg / ml or lower; wherein said second active ingredient comprises a chimeric molecule, which comprises two identical light chains and two identical heavy chain-peptide fusion polypeptide chains; and wherein said light chain comprises an amino acid sequence of SEQ ID NO: 26, and said heavy chain-peptide fusion polypeptide chain comprises an amino acid sequence selected from SEQ ID NOs: 28, 29, 30, 32, 33, 34, 35, and 36.

[0059] In some embodiments, said pharmaceutical composition further comprises a second active ingredient at a concentration of 0.5 mg / ml or higher, a concentration of 1.0 mg / ml or higher, or a concentration of 1.5 mg / ml or higher; wherein said second active ingredient comprises a chimeric molecule, which comprises two identical polypeptide chains which comprise an amino acid sequence selected from SEQ ID NOs: 22- 25.

[0060] In some embodiments, said pharmaceutical composition further comprises a second active ingredient at a concentration of 15.0 mg / ml or lower, concentration of 10.0 mg / ml or lower, or a concentration of 6.0 mg / ml or lower; wherein said second active ingredient comprises a chimeric molecule, which comprises two identical polypeptide chains which comprise an amino acid sequence selected from SEQ ID NOs: 22- 25.BRIEF DESCRIPTION OF THE FIGURES

[0061] FIG. 1 shows WCX-HPLC analysis of a Protein L affinity chromatography pool of the chimeric molecule 03.

[0062] FIG. 2 shows Inhibition of the binding of Ang-2 to Tie-2 by chimeric molecules 03, O3 / QFM and O3 / QF

[0063] FIG. 3 shows WCX-HPLC analysis of the Protein L affinity chromatography elution pools of 03. Black trace: the pH of the elution pool was adjusted after the elution was completed. Blue trace: the elution pool was collected into a container which contained approximately 1.1 column volumes (CVs) of 0.2 M Tris, pH 7.7.14MEl\60901856.vlAttorney Docket No.: 143302-00520

[0064] FIG. 4A shows WCX-HPLC analysis of 03 prior to (blue traces) and after (black traces) low pH viral inactivation with the Protein L affinity chromatography elution pool.

[0065] FIG. 4B shows WCX-HPLC analysis of 03 prior to (blue traces) and after (black traces) low pH viral inactivation with the cation exchange chromatography pool.

[0066] FIG. 5 shows PK of Chimeric Molecule 03 in cynomolgus monkeys dosed I.V. at 36 mg / animal.Definitions

[0067] As used herein and in the appended claims, the singular forms “a,” “or,” and “the” include plural referents unless the context clearly dictates otherwise.

[0068] Reference to “about” a value or parameter herein includes (and describes) variations that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.” Additionally, use of “about” preceding any series of numbers includes “about” each of the recited numbers in that series. For example, description referring to “about X, Y, or Z” is intended to describe “about X, about Y, or about Z.”

[0069] The term “antigen-binding moiety” refers to a polypeptide or a set of interacting polypeptides that specifically bind to an antigen, and includes, but is not limited to, an antibody or antibody fragment, such as a monoclonal antibody, polyclonal, a chimeric antibody, a CDR-grafted antibody, a humanized antibody, a Fab, a Fab', a F(ab')2, a Fv, a disulfide linked Fv, a scFv, a single domain antibody (dAb), a diabody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, a functionally active epitope-binding fragment thereof, bifunctional hybrid antibodies, a single chain antibody, and a Fc-containing polypeptide, such as an immunoadhesion. In some embodiments, the antibody may be of any heavy chain isotype (e.g., IgG, IgA, IgM, IgE, or IgD). In some embodiments, the antibody may be of any light chain isotype (e.g., kappa or gamma). The antibody may be non-human (e.g., from mouse, goat, or any other animal), fully human, humanized, or chimeric. In some embodiments, the antibody is a derivatized antibody.15MEl\60901856.vlAttorney Docket No.: 143302-00520

[0070] The term “effective amount” used herein refers to an amount of a compound or composition sufficient to treat a specified disorder, condition, or disease, such as ameliorate, palliate, lessen, and / or delay one or more of its symptoms. In reference to a disease such as a cancer, an effective amount comprises an amount sufficient to cause a tumor to shrink and / or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation in the cancer. In some embodiments, the effective amount is an amount sufficient to delay development of a cancer. In some embodiments, the effective amount is an amount sufficient to prevent or delay recurrence. An effective amount can be administered in one or more administrations. In the case of a cancer, the effective amount of the drug or composition may: (i) reduce the number of epithelioid cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and preferably stop the cancer cells infiltration into peripheral organs; (iv) inhibit (e.g., slow to some extent and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and / or recurrence of tumor; and / or (vii) relieve to some extent one or more of the symptoms associated with the cancer.

[0071] The term “fused” or “fusion” in reference to two or more polypeptide sequences (such as an antibody heavy chain, antibody light chain, an antibody heavy chain fragment, an antibody light chain fragment, a drug conjugation moiety, a heterologous peptide, an albumin, or an albumin fragment) refers to joining of the polypeptide sequences through a backbone peptide bond.

[0072] The term “pharmaceutically acceptable” when used to refer to a compound or composition means that the compound or composition is suitable for administration to a subject, including a human subject, to achieve the treatments described herein, without unduly deleterious side effects in light of the severity of the disease and necessity of the treatment.

[0073] The term “subject” refers to a mammal and includes, but is not limited to, human, bovine, horse, feline, canine, rodent, or primate.

[0074] As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. For purposes of this invention, beneficial or desired clinical results include, but are not limited to, one or more of the16MEl\60901856.vlAttorney Docket No.: 143302-00520following: alleviating one or more symptoms resulting from a disease, diminishing the extent of a disease, stabilizing a disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread (e.g., metastasis) of a disease, preventing or delaying the recurrence of a disease, delaying or slowing the progression of a disease, ameliorating a disease state, providing remission (partial or total) of a disease, decreasing the dose of one or more other medications required to treat a disease, delaying the progression of a disease, increasing the quality of life, and / or prolonging survival. Also encompassed by “treatment” is a reduction of a pathological consequence of a disease (such as cancer). The methods of the invention contemplate any one or more of these aspects of treatment.

[0075] As used herein, the term "deglycosylation" refers to enzymatically removing sugar moieties from an Fc region, and the term "aglycosylation" means that an Fc region is produced in an unglycosylated form by a prokaryote, preferably E. coli.

[0076] In one embodiment, the immunoglobulin Fc region may be an Fc region that is derived from IgG, IgA, IgD, IgE and IgM, or that is made by combinations thereof or hybrids thereof. Preferably, it is derived from IgG or IgM, which are among the most abundant proteins in human blood, and most preferably from IgG, which is known to enhance the half-lives of ligand-binding proteins.

[0077] The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer. Methods for obtaining (e.g., producing, isolating, purifying, synthesizing, and recombinantly manufacturing) polypeptides are well known to one of ordinary skill in the art.

[0078] It is to be understood that one, some or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.DETAILED DESCRIPTION OF THE INVENTION17MEl\60901856.vlAttorney Docket No.: 143302-00520

[0079] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology as claimed. Additional features and advantages of the subject technology are set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and claims hereof.

[0080] Disclosed herein are fusion proteins and chimeric molecules which comprise two components: an Ang-2 antagonist peptide operationally linked to a VEGF binding domain, which is selected from an anti-VEGF antibody, an anti-VEGF Fab, an anti-VEGF scFv, or a VEGF receptor extracellular domain-Fc fusion protein (or VEGF Trap). The Ang-2 antagonist peptide and VEGF binding domain are each defined below with reference to percent identity to a reference sequence. Further disclosed are methods of using said chimeric molecules to treat a patient of cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

[0081] It is understood that aspects and variations of the invention described herein include “consisting” and / or “consisting essentially of” aspects and variations.Novel Ang-2 Antagonist Peptide

[0082] The fusion protein or chimeric molecule comprises an Ang-2 antagonist peptide component, which binds to Angiopoietin 2 (Ang-2) and inhibits the binding of Ang-2 to its receptor. In some aspect, it is disclosed here novel Ang-2 antagonist peptides which comprises an amino acid sequence selected from SEQ ID NOs: 1-18; wherein said antagonist peptide binds to Ang-2 and inhibits a biological activity of Ang-2. Surprisingly, both O3 / QFM and O3 / QF were active in inhibiting the binding of Ang-2 to its receptor Tie-2 (Fig. 2), even though the Ang-2 antagonist peptides in O3 / QFM with 20 amino acids and O3 / QF with 19 amino acids were substantially shorter than the Ang-2 antagonist peptide in 03 (26 amino acids).VEGF-Binding Moiety18MEl\60901856.vlAttorney Docket No.: 143302-00520

[0083] The chimeric molecule further comprises a VEGF-binding moiety. In one embodiment, said VEGF-binding moiety is an anti-VEGF antibody, an anti-VEGF Fab, or an anti-VEGF scFv that inhibits the binding of VEGF to its receptors. One example of the VEGF antibody comprises a heavy chain variable domain with an amino acid sequence of SEQ ID NO: 20 and a light chain variable domain with an amino acid sequence of SEQ ID NO: 19.

[0084] In another embodiment, said VEGF binding domain is a VEGF receptor ECD-Fc fusion protein which “traps” VEGF (herein, referred to as a “VEGF Trap”) and competes with the naturally occurring VEGF cellular receptor to inhibit VEGF. One example of the VEGF receptor ECD-Fc fusion protein is aflibercept. In some embodiments, said VEGF Trap comprises an amino acid sequence as shown in SEQ ID NO:21.

[0085] In some embodiments, the VEGF-binding moiety comprises the six complementarity determining regions (CDRs) of Brolucizumab (RTH258), Ranibizumab or Bevacizumab. A number of CDR delineations are known in the art and are encompassed herein. A person of skill in the art can readily determine a CDR for a given delineation based on the sequence of the heavy or light chain variable region. The “Kabat” Complementarity Determining Regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)). “Chothia” CDRs refer to the location of the structural loops (Chothia & Lesk, Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., vol. 196, pp. 901-917 (1987)). The “AbM” CDRs represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular’s AbM antibody modeling software. The “Contact” CDRs are based on an analysis of the available complex crystal structures. The residues from each of these CDRs are noted below in Table 1 , in reference to common antibody numbering schemes. Unless otherwise specified herein, amino acid number of antibodies refers to the Kabat numbering scheme as described in Kabat et al., supra, including when CDR delineations are made in reference to Kabat, Chothia, AbM, or Contact schemes. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional19MEl\60901856.vlAttorney Docket No.: 143302-00520amino acids corresponding to a shortening of, or insertion into, a framework region (FR) or CDR of the variable domain. For example, a heavy-chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy-chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence.Table 1 : CDR Delineations According to Various SchemesCDR Kabat AbM Chothia Contact VL-CDR1 L24— L34 L24— L34 L26— L32 L30— L36 VL-CDR2 L50— L56 L50— L56 L50— L52 L46— L55 VL-CDR3 L89— L97 L89— L97 L91— L96 L89— L96 VH-CDR1 (Kabat Numbering) H31— H35B H26— H35B H26— H32 H30— H35B VH-CDR1 (Chothia Numbering) H31— H35 H26— H35 H26— H32 H30— H35 VH-CDR2 H50— H65 H50— H58 H53— H55 H47— H58 VH-CDR3 H95— H102 H95— H102 H95— H101 H93— H101

[0086] In some embodiments, the CDRs are “extended CDRs,” and encompass a region that begins or terminates according to a different scheme. For example, an extended CDR can be as follows: L24— L36, L26— L34, or L26— L36 (VL-CDR1); L46— L52, L46— L56, or L50— L55 (VL-CDR2); L91— L97 (VL-CDR3); H47— H55, H47— H65, H50— H55, H53— H58, or H53— H65 (VH-CDR2); and / or H93— H102 (VH-CDR3).Ang-2 antagonist peptide - VEGF-Binding Moiety Fusion Protein

[0087] The Ang-2 peptide can be linked or fused to either the C- or N- terminus of the VEGF antibody (e.g., either the heavy or the light chains) or the VEGF receptor-Fc fusion protein. The Fc portion of the VEGF receptor-Fc fusion protein may be located at either the C- or N-terminus of the VEGF receptor protein. The Fc portion is further defined herein.

[0088] The present compositions include “Fc fragments” or “Fc regions.” The term “Fc fragment” or "immunoglobulin Fc region" as used herein, refers to a protein that contains at least the heavy-chain constant region 2 (CH2) and the heavy-chain constant region 3 (CH3) of an immunoglobulin. In one embodiment, the Fc region 20MEl\60901856.vlAttorney Docket No.: 143302-00520excludes the variable regions of the heavy and light chains, the heavy-chain constant region 1 (CH1 ) and the light-chain constant region 1 (CL1 ) of the immunoglobulin. The Fc region may further include a hinge region at the heavy-chain constant region. Also, the immunoglobulin Fc region disclosed herein may contain a part or all of the Fc region including the heavy-chain constant region 1 (CH1) and / or the light-chain constant region 1 (CL1), except for the variable regions of the heavy and light chains, as long as it has a physiological function substantially similar to or better than the native protein. Also, the immunoglobulin Fc region may be a fragment having a deletion in a relatively long portion of the amino acid sequence of CH2 and / or CH3. That is, the immunoglobulin Fc region disclosed herein may comprise 1) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or more domains and an immunoglobulin hinge region (or a portion of the hinge region), and 6) a dimer of each domain of the heavychain constant regions and the light-chain constant region.

[0089] The immunoglobulin Fc region disclosed herein includes a native amino acid sequence, or a sequence analogue thereof. An amino acid sequence analogue is a sequence that is different from the native amino acid sequence due to a deletion, an insertion, a non-conservative or conservative substitution or combinations thereof of one or more amino acid residues.

[0090] Also, other various analogues are possible, including one in which a region capable of forming a disulfide bond is deleted, or certain amino acid residues are eliminated at the N-terminal end of a native Fc form or a methionine residue is added thereto. Further, to remove effector functions, a deletion may occur in a complementbinding site, such as a C1q-binding site and an ADCC (antibody dependent cell mediated cytotoxicity) site. Techniques of preparing such sequence analogues of the immunoglobulin Fc region are disclosed in WO 1997 / 034631 and WO 1996 / 032478.

[0091] The aforementioned Fc analogues are analogues that have a biological activity identical to the Fc region disclosed herein or improved structural stability, for example, against heat, pH, or the like.21MEl\60901856.vlAttorney Docket No.: 143302-00520

[0092] In addition, these Fc regions may be obtained from native forms isolated from humans and other animals including cows, goats, pigs, mice, rabbits, hamsters, rats and guinea pigs, or may be recombinants or analogues thereof, obtained from transformed animal cells or microorganisms. Herein, they may be obtained from a native immunoglobulin by isolating whole immunoglobulins from human or animal organisms and treating them with a proteolytic enzyme. Papain digests the native immunoglobulin into Fab and Fc regions, and pepsin treatment results in the production of pF'c and F(ab)2 fragments. These fragments may be subjected, for example, to size exclusion chromatography to isolate Fc or pF'c. Preferably, a human-derived Fc region is a recombinant immunoglobulin Fc region that is obtained from a microorganism.

[0093] In one embodiment, the Fc region, if desired, may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation, amidation, and the like. In one embodiment, the immunoglobulin Fc region disclosed herein may be in the form of having native sugar chains, increased sugar chains compared to a native form or decreased sugar chains compared to the native form, or may be in a deglycosylated form. The increase, decrease or removal of the immunoglobulin Fc sugar chains may be achieved by methods common in the art, such as a chemical method, an enzymatic method and a genetic engineering method using a microorganism. The removal of sugar chains from an Fc region results in a sharp decrease in binding affinity to the C1q part of the first complement component C1 and a decrease or loss in antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity, thereby not inducing unnecessary immune responses in-vivo. In this regard, an immunoglobulin Fc region in a deglycosylated or aglycosylated form may be more suitable as a drug carrier.

[0094] In some embodiments, the Fc region is an IgG 1 Fc region with LALA mutations (e.g., mutations that abolish Fc gamma effector function). In some embodiments, the Fc region is an IgG 1 Fc region with one or more (e.g., 1 , 2, 3, or more) mutations specifically engineered to abolish FcRn binding and reduce systemic half-life after intraocular administration. In some embodiments, the one or more mutations specifically engineered to abolish FcRn binding are selected from the group consisting of I253A, H310A, and H435A. In some embodiments, the lgG122MEl\60901856.vlAttorney Docket No.: 143302-00520Fc region comprises I253A, H310A, and H435A mutations. In some embodiments, the lgG1 Fc region comprises LALA, I253A, H310A, and H435A mutations.Pharmaceutical Compositions

[0095] Pharmaceutical compositions of the prodrugs are prepared by mixing the antibody fusion molecules or the antibody fusion molecule drug conjugate having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (see Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed.(1980)), in the form of lyophilized formulations or aqueous solutions.Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG). Buffers are used to control the pH in a range which optimizes the therapeutic effectiveness, especially if stability is pH dependent.Buffers are preferably present at concentrations ranging from about 10 mM to about 50 mM. Suitable buffering agents for use with the present invention include both organic and inorganic acids and salts thereof, such as citrate, phosphate, succinate, tartrate, fumarate, gluconate, oxalate, lactate, acetate. Additionally, buffers may comprise histidine and trimethylamine salts such as Tris.EXAMPLES

[0096] The following non-limiting examples are provided for illustrative purposes only in order to facilitate a more complete understanding of representative23MEl\60901856.vlAttorney Docket No.: 143302-00520embodiments now contemplated. These examples should not be construed to limit any of the embodiments described in the present specification, including those pertaining to the compounds, pharmaceutical compositions, or methods and uses disclosed herein.Example 1 - Blocking of Ang-2 / Tie-2 Binding as Analysed by ELISA

[0097] The chimeric molecules were assessed in their abilities in blocking the binding of Ang1 and Ang2 to their receptor Tie-2. 96 well microtiter plate (Nunk) was coated with 100 uL final concentration 100 ng / mL of human Tie2-Fc (R&D System, 313-T 1 ) diluted in 0.1 M carbonate (pH9.3) at 4 oC overnight. The plate was then blocked for 2 hours with 5% BSA in PBST (0.05% Tween 20). Purified chimeric molecule, at starting concentration of 1000 ng / mL, was serially diluted with dilution factor of three in PBS with 1% BSA. Human Ang1 or Ang2 protein (R&D System) was added to final concentration of 50 ng / mL and incubated at room temperature for 1 hour. The Chimeric molecule-Ang1 or Chimeric molecule-Ang2 mixture was then added into microtiter plate coated with human Tie2-Fc and incubate for another 1 hour at room temperature. 100 uL anti-Ang1 or anti-Ang2 monoclonal antibody (R&D System) was added into each well at final concentration of 1 ug / mL and incubated for 1 hour at room temperature. Horseradish-peroxidase (HRP) conjugated anti-mouse IgG secondary antibody was added at 1 :5000 dilution and incubated for 1 hour at room temperature. Standard colorimetric response was developed by using TMB (Pierce). Absorbance was read at OD450 by spectrophotometer. Between each step, the plate was washed 5 time with 100 uL PBS.

[0098] FIG. 2 shows the inhibition of the binding of Ang-2 to Tie-2 by chimeric molecules 03, O3 / QFM and O3 / QF (see below).Example 2 - Blocking of VEGF / VEGFR Binding by Chimeric Molecules as Analysed by ELISAMaterials:• NUNC 96 well Maxisorp flat-bottom ELISA plate purchased from Thermo Fisher Scientific, Cat# 44-2404-21• Recombinant human VEGFR2-Fc protein, purchased from R&D system, Cat# 357-KD24MEl\60901856.vlAttorney Docket No.: 143302-00520• Recombinant human VEGF165, purchased from Sino Biological, Cat# 11066- HNAB• Anti- human VEGF-biotinylated antibody, purchased from R&D System, Cat# BAF293• Peroxidase-conjugated streptavidin secondary, purchased from Jackson Immuno-Research Lab, Cat# 016030-084• TMB ELISA substrate kit, purchased from Thermo Fisher Scientific, Cat#34021• ELISA washing buffer, PBS / no calcium and magnesium / pH 7.2 / 0.05% tween 20.• Blocking buffer, washing buffer / 5% BSA• VEGF / chimeric molecule incubation buffer, washing buffer / 1 % BSAProcedure:

[0099] Coat ELISA plate: VEGFR protein was diluted with PBS to 100 ng / ml, add 100 ul diluted VEGFR into ELISA plate, covered the plate with plate sealer. The plate was put in 4 C refrigerator for overnight. 0.1 nM human VEGF165 was incubated with a chimeric molecule which was diluted 1 :3 to 10 points with incubation buffer, starting concentration with 6 ug / ml, Final volume is 200 ul, incubation overnight at room temperature. Washing the plate with 200 ul washing buffer 3x.

[0100] Blocking the plate with washing buffer / 5% BSA for 2 hrs at room temperature. Repeat step#3. Add 185 ul of step#2 mixture to plate and incubate for 1 hr at room temperature with plate sealer. Washing the plate with 200 ul washing buffer 4x.

[0101] Add 100 ul anti-human VEGF-biotinylated antibody at final concentration 0.2 ug / ml and incubate for 1 hour at room temperature with plate sealer. Repeat step#7. Add 100 ul peroxidase-conjugated streptavidin at 0.1 ug / ml and incubate for 1 hour at room temperature with plate sealer. Repeat step #7 Add 100 ul TMB substrate and incubate to desired time.Add 100 ul 1 M HSO4 to stop reactionRead the plate using Spectra Max at Wavelengths 45025MEl\60901856.vlAttorney Docket No.: 143302-00520Example 3 - Novel Ang-2 Antagonist Peptides

[0102] A chimeric molecule named 03 comprises two identical light chains of SEQ ID NO: 30 and two identical heavy chain-peptide fusion polypeptides of SEQ ID NO: 31. When 03 was expressed by a CHO cell line and purified, it was discovered that it comprises multiple charge variants as analyzed by an ion exchange HPLC method (FIG. 1). Further analysis of an enriched fraction of the basic peaks by mass spectroscopy showed that, surprisingly, the Ang-2 antagonist peptide moiety of the chimeric molecule 03 was clipped from the C-terminus and several variants of the chimeric molecule were formed (Table 2). The genes of two variants of the chimeric molecules named O3 / QFM and 03 / QF were synthesized, wherein O3 / QFM comprises the Ang-2 antagonist peptide of SEQ ID NO: 5 and wherein 03 / QF comprises the Ang-2 antagonist peptide of SEQ ID NO: 6. Both molecules were expressed recombinantly and purified. Surprisingly, both O3 / QFM and 03 / QF were active in inhibiting the binding of Ang-2 to its receptor Tie-2 (Fig. 2), even though the Ang-2 antagonist peptides in O3 / QFM with 20 amino acids and 03 / QF with 19 amino acids were substantially shorter than the Ang-2 antagonist peptide in 03 (26 amino acids).

[0103] FIG. 1 shows WCX-HPLC analysis of a Protein L affinity chromatography pool of the chimeric molecule 03.Table 2. Mass spectroscopy analysis of an enriched basic fraction of the chimeric molecule 03Number of Ang-2 antagonist peptide sequence Theoretical Detected PI amino acids Mass (D) Mass (D) (calculated clipped from the based on C-terminus of sequence) the HC-peptidefusionAQQKYQPLDELDKTLYDQFMLQQGLE0 (intact) 53679.66 53673 6.776 (SEQ ID NO: 39)AQQKYQPLDELDKTLYDQFMLQQG2 53437.38 53431 7.006 (SEQ ID NO: 1)AQQKYQPLDELDKTLYDQFMLQ4 53252.20 53245 7.006 (SEQ ID NO: 3)7 AQQKYQPLDELDKTLYDQF 52879.72 52873 7.00626MEl\60901856.vlAttorney Docket No.: 143302-00520(SEQ ID NO: 6)AQQKYQPLDELDKTLY10 52489.33 52599 7.247 (SEQ ID NO: 9)

[0104] FIG. 2 shows Inhibition of the binding of Ang-2 to Tie-2 by chimeric molecules 03, 03 / QFM and O3 / QFExample 4 - Protein L Affinity Chromatography

[0105] The Protein L affinity chromatography was used as the capturing step for the chimeric molecule 03 from the CHO cell culture. It was carried out with AF-rProtein L-650F resin from Tosoh Bioscience. The column was sanitized with 50 mM NaOH for 10-15 min and equilibrated with 50 mM Tris-HCI, 150 mM NaCL, pH approximate 7.2. The column was loaded with the chimeric molecule 03 at up to 30 g / L. The column was washed with a buffer comprising 50mM Tris-Tris HOI, 1 M Arg HOI, pH 7.4, or a buffer comprising 50 mM Tris, 0.4 M Arginine, 1.5 M NaCI, pH8.5, and equilibrated. The column was eluted with 100 mM glycine, pH approximately 2.5, or 50 mM citric acid, pH approximately 2.9. The pH of the elution pool was neutralized under various conditions (Table 3 and Fig. 3). The column was stripped and regenerated for additional cycles.

[0106] In one embodiment, the product elution was collected into a container which contained 0.3 column volumes (CVs) of 0.2 M Tris, pH 8.5 (Table 3) or approximately 1.1 CVs of 0.2M Tris, pH 7.7 (Fig. 3) in order to adjust the pH up at the same time while elution. It was surprised to discover that the elution pools collected into a container containing the Tris buffers had the highest or higher main peak purity and lowest basic peak% as analyzed by a weak cation exchange HPLC (WCX-HPLC).MEl\60901856.vlAttorney Docket No.: 143302-00520

[0107] Table 3. pH adjustment post Protein L Affinity Chromatography Elution (0476 p028 BPI202004020)WCX-HPLCStep pH Adjustment SEC-HPLC (%) Main PeakYield (%) (%)Aggregates FragmentsMain% %No pH adjustment 71.4 5.7 22.9 17.9 110.1 Adjusted to pH 6.0 after 175.2 1.9 22.9 22.0 / hr holdAdjusted to pH 5.474.8 1.8 23.4 25.2 / immediately after elutionAdjusted to pH 6.074.9 2.2 22.9 26.0 / immediately after elutionCollected elution into acontainer with pH74.9 2.4 22.7 30.4 109.7 neutralizing solution andadjusted pH to pH 6.0

[0108] FIG. 3. shows WCX-HPLC analysis of the Protein L affinity chromatography elution pools of 03. Black trace: the pH of the elution pool was adjusted after the elution was completed. Blue trace: the elution pool was collected into a container which contained approximately 1.1 column volumes (CVs) of 0.2 M Tris, pH 7.7.Example 5 - Low pH Viral Inactivation

[0109] Low pH viral inactivation is an important step often used in the downstream process for recombinant therapeutics produced by mammalian cell culture. The low pH viral inactivation step was carried out for the chimeric molecule 03 after the Protein L affinity chromatography or after the third chromatography step which was a cation exchange chromatography. In one embodiment, said cation exchange chromatography is carried out with the Capto SP Impres resin or equivalent. In each case, the column pool of the Protein L affinity chromatography or the product pool of the cation exchange chromatography was pH adjusted to about 3.6, incubated for approximately 1 hour at room temperature, and then the pH adjusted up to approximately 5.5 or 6.0. It was noticed that the weak cation28MEl\60901856.vlAttorney Docket No.: 143302-00520exchange (WCX)-HPLC main peak purity decreased significantly after the low pH viral inactivation (FIG. 4A). It was surprising to discover that the WCX-HPLC main peak purity for the cation exchange pool did not change after the low pH viral inactivation (FIG. 4B).

[0110] The product quality results of the Protein L affinity chromatography pools from various conditions showed that the chimeric molecule 03 is more stable at a pH of 6.0 compared with a lower pH right after the affinity column elution. The low pH viral inactivation pools started with the first column step and the third column step showed that when the chimeric molecule was further purified, it becomes more stable at a lower pH such as pH 3.6. In both cases, the decrease of the WCX-HPLC main peak were correlated with an increase of the basic peaks, which suggested the Ang-2 antagonist peptide moiety of the chimeric molecule was clipped from the C-terminus. While not wished to be limited by theory, it is proposed here that the degradation of the 03 molecule at a lower pH during the earlier steps of purification was potentially caused of a protease or proteases which are active at acidic pH such as pH 3.6 or having significantly stronger activity at a pH lower than 6.0 than at pH 6.0. In one embodiment, the expression host cell line such as the CHO cell line is engineered to eliminate the gene or genes of said protease or proteases which are active at an acidic pH or a pH of approximately 3.6. In one embodiment, said gene or genes are knocked out optionally using a method such as CRISPER.

[0111] FIG. 4A and 4B show WCX-HPLC analysis of 03 prior to (blue traces) and after (black traces) low pH viral inactivation with the Protein L affinity chromatography elution pool (FIG.4A) and the cation exchange chromatography pool (FIG. 4B).Example 6 - Binding affinity with Fc receptors

[0112] The targets of the Chimeric Molecule 03 are VEGF and Ang-2, both of which are soluble factors. Therefore, there are no direct target cells, and no studies on ADCC (antibody-dependent cellular cytotoxicity) or CDC (complement-dependent cytotoxicity) were conducted.

[0113] The binding ability of the Chimeric Molecule 03 to Fc receptors (FcR) was assessed using surface plasmon resonance (SPR). The affinities of the29MEl\60901856.vlAttorney Docket No.: 143302-00520Chimeric Molecule 03 for FcRn, FcyRI, FcyRlla, and FcyRllla were evaluated, with the wild-type IgG 1 Fc antibody (Bevacixumab analog) used as a control. The results are as shown in Table 4. The results showed that the Chimeric Molecule 03 with the Fc domain mutations has significantly reduced binding affinities to Fc receptors compared to the wild type IgG 1 Fc.

[0114] Table 4. Comparison of Fc receptor binding affinities of the Chimeric Molecule 03 vs a wild type IgG 1 Fc.C1q FcRn FcyRla FcyRlla FcyRlla FcyRllla FcyRllla (R167) (H167) (F176) (V176) Bevacizumab 1.92E-07 4.48E-07 1.31 E-08 7.20E-06 5.36E-06 3.23E-06 3.96E-07 analog (withwild typelgG1 Fc)(nM)Chimeric 4.27E-06 No No No No 2.38E-05 7.80E-06 Molecule 03 Binding Binding Binding Binding(nM)Reduction in 22.2x 7.4x 19.7x bindingaffinity (Fold)Example 7 - PK in cynomolgus monkeys

[0115] PK of the chimeric molecule 03 was carried out in cynomolgus monkeys. Two animals, one male and one female, were dosed at 36 mg per animal through intravenous administration. Blood samples were collected at the following time points: before the first and last doses, and at 5 min, 4 h, 8 h, 24 h, Day 2 (D2), Day 3 (D3), Day 5 (D5), Day 7 (D7), Day 14 (D14), and Day 28 (D28) after dosing. The sample type was serum. The concentrations of the Chimeric Molecule 03 in the serum samples were analyzed using the MSD method, which detected targets with unoccupied binding sites for both VEGF and Ang-2. FIG. 5 shows PK of Chimeric Molecule 03 in cynomolgus monkeys dosed I.V. at 36 mg / animal. Consistent with the abolished binding to FcRN, the half-life of 03 in the cynomolgus monkeys was about 17 hours (data not shown), significantly shorter than a regular IgG 1 antibody with a wild type Fc domain.30MEl\60901856.vlAttorney Docket No.: 143302-00520This shorter half-life of 03 would allow faster clearance in the circulation and lead to reduced systemic toxicity and better safety.

[0116] In closing, it is to be understood that although aspects of the present specification are highlighted by referring to specific embodiments, one skilled in the art will readily appreciate that these disclosed embodiments are only illustrative of the principles of the subject matter disclosed herein. Therefore, it should be understood that the disclosed subject matter is in no way limited to a particular compound, composition, article, apparatus, methodology, protocol, and / or reagent, etc., described herein, unless expressly stated as such. In addition, those of ordinary skill in the art will recognize that certain changes, modifications, permutations, alterations, additions, subtractions and sub-combinations thereof can be made in accordance with the teachings herein without departing from the spirit of the present specification. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such changes, modifications, permutations, alterations, additions, subtractions and subcombinations as are within their true spirit and scope.

[0117] Certain embodiments of the present invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the present invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.Moreover, any combination of the above-described embodiments in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[0118] Groupings of alternative embodiments, elements, or steps of the present invention are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other group members disclosed herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and / or 31MEl\60901856.vlAttorney Docket No.: 143302-00520patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0119] Unless otherwise indicated, all numbers expressing a characteristic, item, quantity, parameter, property, term, and so forth used in the present specification and claims are to be understood as being modified in all instances by the term “about.” As used herein, the term “about” means that the characteristic, item, quantity, parameter, property, or term so qualified encompasses a range of plus or minus ten percent above and below the value of the stated characteristic, item, quantity, parameter, property, or term. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary. For instance, as mass spectrometry instruments can vary slightly in determining the mass of a given analyte, the term "about" in the context of the mass of an ion or the mass / charge ratio of an ion refers to + / -0.50 atomic mass unit. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical indication should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0120] Use of the terms “may” or “can” in reference to an embodiment or aspect of an embodiment also carries with it the alternative meaning of “may not11or “cannot.” As such, if the present specification discloses that an embodiment or an aspect of an embodiment may be or can be included as part of the inventive subject matter, then the negative limitation or exclusionary proviso is also explicitly meant, meaning that an embodiment or an aspect of an embodiment may not be or cannot be included as part of the inventive subject matter. In a similar manner, use of the term “optionally” in reference to an embodiment or aspect of an embodiment means that such embodiment or aspect of the embodiment may be included as part of the inventive subject matter or may not be included as part of the inventive subject matter. Whether such a negative limitation or exclusionary proviso applies will be based on whether the negative limitation or exclusionary proviso is recited in the claimed subject matter.32MEl\60901856.vlAttorney Docket No.: 143302-00520

[0121] Notwithstanding that the numerical ranges and values setting forth the broad scope of the invention are approximations, the numerical ranges and values set forth in the specific examples are reported as precisely as possible. Any numerical range or value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Recitation of numerical ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate numerical value falling within the range. Unless otherwise indicated herein, each individual value of a numerical range is incorporated into the present specification as if it were individually recited herein.

[0122] The terms “a,” “an,” “the” and similar references used in the context of describing the present invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Further, ordinal indicators - such as “first,” “second,” “third,” etc. - for identified elements are used to distinguish between the elements, and do not indicate or imply a required or limited number of such elements, and do not indicate a particular position or order of such elements unless otherwise specifically stated. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the present invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the present specification should be construed as indicating any nonclaimed element essential to the practice of the invention.

[0123] When used in the claims, whether as filed or added per amendment, the open-ended transitional term “comprising” (and equivalent open-ended transitional phrases thereof like including, containing and having) encompasses all the expressly recited elements, limitations, steps and / or features alone or in combination with unrecited subject matter; the named elements, limitations and / or features are essential, but other unnamed elements, limitations and / or features may be added and still form a construct within the scope of the claim. Specific embodiments disclosed herein may be further limited in the claims using the closed-33MEl\60901856.vlAttorney Docket No.: 143302-00520ended transitional phrases “consisting of” or “consisting essentially of” in lieu of or as an amended for “comprising.” When used in the claims, whether as filed or added per amendment, the closed-ended transitional phrase “consisting of” excludes any element, limitation, step, or feature not expressly recited in the claims. The closed-ended transitional phrase “consisting essentially of” limits the scope of a claim to the expressly recited elements, limitations, steps and / or features and any other elements, limitations, steps and / or features that do not materially affect the basic and novel characteristic(s) of the claimed subject matter. Thus, the meaning of the open-ended transitional phrase “comprising” is being defined as encompassing all the specifically recited elements, limitations, steps and / or features as well as any optional, additional unspecified ones. The meaning of the closed-ended transitional phrase “consisting of” is being defined as only including those elements, limitations, steps and / or features specifically recited in the claim whereas the meaning of the closed-ended transitional phrase “consisting essentially of” is being defined as only including those elements, limitations, steps and / or features specifically recited in the claim and those elements, limitations, steps and / or features that do not materially affect the basic and novel characteristic(s) of the claimed subject matter. Therefore, the open-ended transitional phrase “comprising” (and equivalent open-ended transitional phrases thereof) includes within its meaning, as a limiting case, claimed subject matter specified by the closed-ended transitional phrases “consisting of” or “consisting essentially of.” As such embodiments described herein or so claimed with the phrase “comprising” are expressly or inherently unambiguously described, enabled and supported herein for the phrases “consisting essentially of” and “consisting of.”

[0124] All patents, patent publications, and other publications referenced and identified in the present specification are individually and expressly incorporated herein by reference in their entirety for the purpose of describing and disclosing, for example, the compositions and methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these 34MEl\60901856.vlAttorney Docket No.: 143302-00520documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.

[0125] Lastly, the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Accordingly, the present invention is not limited to that precisely as shown and described.SEQUENCESL1 -15 Peptide AnalogsAQQKYQPLDELDKTLYDQFMLQQG (SEQ ID NO:1) AQQKYQPLDELDKTLYDQFMLQQ (SEQ ID NO:2) AQQKYQPLDELDKTLYDQFMLQ (SEQ ID NO:3)AQQKYQPLDELDKTLYDQFML (SEQ ID NO:4)AQQKYQPLDELDKTLYDQFM (SEQ ID NO:5)AQQKYQPLDELDKTLYDQF (SEQ ID NO:6)AQQKYQPLDELDKTLYDQ (SEQ ID NO:7)AQQKYQPLDELDKTLYD (SEQ ID NO:8)AQQKYQPLDELDKTLY (SEQ ID NO:9)QKYQPLDELDKTLYDQFMLQQG (SEQ ID NO:10) QKYQPLDELDKTLYDQFMLQQ (SEQ ID NO:11)QKYQPLDELDKTLYDQFMLQ (SEQ ID NO:12)QKYQPLDELDKTLYDQFML (SEQ ID NO:13)QKYQPLDELDKTLYDQFM (SEQ ID NO:14)QKYQPLDELDKTLYDQF (SEQ ID NO:15)QKYQPLDELDKTLYDQ (SEQ ID NO:16)QKYQPLDELDKTLYD (SEQ ID NO:17)QKYQPLDELDKTLY (SEQ ID NO:18)SEQ ID NO: 19 Ranibizumab Light Chain Variable Domain DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVP SRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFP35MEl\60901856.vlAttorney Docket No.: 143302-00520PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYE KH KVYACEVTHQG LSSPVTKSFN RG ECSEQ ID NO: 20 Ranibizumab Heavy Chain Variable Domain EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSSEQ ID NO: 21 VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGSEQ ID NO: 22 L1 -15 analog 5 fused to C-terminal VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGAGGGGSGGGSGGGGSAQQKYQPLDELDKTLYDQFMLQQGSEQ ID NO: 23 L1 -15 analog 6 fused to C-terminal of a VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW36MEl\60901856.vlAttorney Docket No.: 143302-00520LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGAGGGGSGGGGSGGGGSAQQKYQPLDELDKTLYDQFMLSEQ ID NO: 24, L1 -15 analog 7 fused to C-terminal of a VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGAGGGGSGGGGSGGGGSAQQKYQPLDELDKTLYDQFMSEQ ID NO: 25, L1 -15 analog 8 fused to C-terminal of a VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGAGGGGSGGGGSGGGGSAQQKYQPLDELDKTLYDQFSEQ ID NO: 26 Light Chain DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVP SRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYE KH KVYACEVTHQG LSSPVTKSFN RG ECSEQ ID NO: 27 Heavy Chain-L1 -15 EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG37MEl\60901856.vlAttorney Docket No.: 143302-00520VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSAQQKYQPLDELDKTLYDQFMLQQGLESEQ ID NO: 28 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSAQQKYQPLDELDKTLYDQFMLSEQ ID NO: 29 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSAQQKYQPLDELDKTLYDQFMSEQ ID NO: 30 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT38MEl\60901856.vlAttorney Docket No.: 143302-00520CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSAQQKYQPLDELDKTLYDQFSEQ ID NO: 31 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSAQQKYQPLDELDKTLYDQFMLQQGLESEQ ID NO: 32 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSQKYQPLDELDKTLYDQFMLSEQ ID NO: 33 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV39MEl\60901856.vlAttorney Docket No.: 143302-00520EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSQKYQPLDELDKTLYDQFMSEQ ID NO: 34 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSQKYQPLDELDKTLYDQFSEQ ID NO: 35 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSAQQKYQPLDELDKTLYDQFMLQQGSEQ ID NO: 36 Heavy Chain-L1 -15 Analog EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG40MEl\60901856.vlAttorney Docket No.: 143302-00520QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGAGGGGSGGG GSGGGGSQKYQPLDELDKTLYDQFMLQQGSEQ ID NO: 37, L1 -15 fused to C-terminal of a VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGAGGGGSGGGGSGGGGSAQQKYQPLDELDKTLYDQFMLQQ GLESEQ ID NO: 38, L1 -15 analog fused to C-terminal of a VEGF Trap SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRK GFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNC TARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLY TCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY PSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGAGGGGSGGGGSGGGGSQKYQPLDELDKTLYDQFMLQQGLESEQ ID NO: 39, Ang-2 antagonist peptide L1 -15 AQQKYQPLDELDKTLYDQFMLQQGLESEQ ID NO: 40, anti-VEGF Heavy Chain EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTG EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCPAPEAAGGPSVFLFPPKPKDTLMASRTPEVTCVVVDVSHEDPEVKFNWYVDGV41MEl\60901856.vlAttorney Docket No.: 143302-00520EVHNAKTKPREEQYNSTYRVVSVLTVLAQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNAYTQKSLSLSPGA42MEl\60901856.vl

Claims

Attorney Docket No.: 143302-00520CLAIMSWhat is claimed is:

1. An antagonist peptide which binds to Ang-2 and inhibits a biological activity of Ang-2, comprising, consisting essentially of, or consisting of an amino acid sequence selected from any one of SEQ ID NOs: 1-18, such as any one of SEQ ID NOs: 2-4, 7-9, and 11-18.

2. A chimeric molecule comprising the Ang-2 antagonist peptide of claim 1 , and an anti-vascular endothelial growth factor (VEGF) antibody or antigen-binding fragment thereof.

3. The chimeric molecule of claim 2, wherein the anti-VEGF antibody or antigenbinding fragment thereof comprises two identical light chains each comprising the amino acid sequence of SEQ ID NO: 26 and two identical heavy chains each comprising the amino acid sequence of SEQ ID NO: 40.

4. The chimeric molecule of claim 3, wherein the Ang-2 antagonist peptide is linked to the C-terminus of one of the heavy chains via an amino acid linker.

5. The chimeric molecule of claim 4, wherein the chimeric molecule comprises a second Ang-2 antagonist peptide linked to the C-terminus of the other heavy chain via an amino acid linker, and wherein the second Ang-2 antagonist peptide comprises an amino acid sequence selected from any one of SEQ ID NOs: 2-4, 7-9, and 11-18.

6. A chimeric molecule comprising the Ang-2 antagonist peptide of claim 1 , and a VEGF Trap; optionally whereinsaid VEGF Trap comprises the amino acid sequence of SEQ ID NO: 21 ; and / orsaid Ang-2 antagonist peptide is linked to the C-terminus of the VEGF Trap via an amino acid linker.

7. An isolated polynucleotide encoding the chimeric molecule of any one of claims 2-6.

8. An expression vector comprising the polynucleotide of claim 7.

9. A host cell transfected with the polynucleotide of claim 7 or the expression vector of claim 8.43MEl\60901856.vlAttorney Docket No.: 143302-0052010. A method of making the chimeric molecule of any one of claims 2-6, comprising culturing the host cell of claim 9 under conditions that allow expression of the chimeric molecule, and isolating the chimeric molecule.

11. A method of purifying the chimeric molecule of any one of claims 2-6, where the method comprises an affinity chromatography as its first chromatography step, which is eluted with an acidic solution with a pH of 2.4 - 4.0; and wherein the product eluant is collected into a vessel which contains a pH neutralization solution with optional mixing.

12. A method of purifying the chimeric molecule of any one of claims 2-6, where the method comprises an affinity chromatography as its first chromatography step, which is eluted with an acidic solution with a pH of 2.4 - 4.0; and wherein the pH of the product eluant is adjusted simultaneously or on-line during the elution with a pH neutralization solution.

13. A method of purifying a chimeric molecule comprising an affinity chromatography, wherein the affinity chromatography is eluted with an acidic solution with a pH of 2.4 - 4.0;wherein the product eluant is collected into a container which contains a pH neutralization solution, or the pH of the product eluant is adjusted simultaneously on-line during the elution with a pH neutralization solution; and wherein the chimeric molecule comprises an Ang-2 antagonist peptide which comprises the amino acid sequence of SEQ ID NO: 39 or a functional analog thereof.

14. The method of claim 13, wherein the chimeric molecule comprises a light chain comprising the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence having at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO: 26, and a heavy chain-peptide fusion polypeptide chain comprising the amino acid sequence of SEQ ID NO: 27 or 31 or an amino acid sequence having at least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO: 27 or 31.

15. The method of claim 13, wherein the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 37 or 38 or an amino acid sequence having at 44MEl\60901856.vlAttorney Docket No.: 143302-00520least 90% (e.g., at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) identity to the amino acid sequence of SEQ ID NO: 37 or 38.

16. The method of claim 13 or 14, wherein the affinity chromatography is a Protein L affinity chromatography; andwherein the solution used to elute the product from the affinity column (or Elution Buffer) has a pH of approximately 2.5, approximately 2.6, approximately 2.7, approximately 2. approximately 2.8, approximately 2.9, approximately 3.0, approximately 3.1, approximately 3.2, approximately 3.3, approximately 3.4, approximately 3.5, approximately 3.6, approximately 3.7, approximately 3.8, approximately 3.9, or approximately 4.0; and wherein the resulted affinity column elution pool (e.g., the product eluant mixed with the pH neutralization solution either on-line or in the collection container) has a pH of 4.5 to 8.5, a pH of 5.5 to 7.5, a pH of 5.5 to 6.5, or a pH of approximately 6.0.

17. The method of any one of claims 13, 14 and 16, wherein the affinity chromatography is a Protein L affinity chromatography,wherein the chromatography comprises a washing step after loading; and wherein said washing step using a solution comprising 0.4 - 2.0 M arginine, pH 7.0-8.5.

18. The method of any one of claims 13, 14 and 16, wherein the affinity chromatography is a Protein L affinity chromatography, wherein the chromatography comprises an elution step; and wherein the elution step uses an elution buffer comprising approximately 100 mM glycine with a pH of approximately 2.5, or a solution comprising approximately 50 mM citric acid with a pH of approximately 2.9.

19. The method of any one of claims 13-18, wherein the pH neutralization solution comprises Tris, bis-tris, Histidine, citrate, or arginine at a concentration of 0.01 - 3.0 M.

20. The method of any one of claims 13-18, wherein the product eluant is collected into a vessel which contains approximately 0.3 column volumes (CVs) of the neutralization solution; and wherein the neutralization solution comprises approximately 0.25 M Tris with a pH of approximately 8.5.45MEl\60901856.vlAttorney Docket No.: 143302-0052021. The method of any one of claims 13-20, further comprising a second, a third and an optional fourth chromatography steps, a low pH viral inactivation step, and additional process steps; wherein the low pH viral inactivation step is carried out after the second chromatography step, or after the third chromatography step.

22. The method of any one of claims 13-21 , which comprises the following steps with optional filtration step or steps before and / or after each chromatography step:a) clarification of the cultured cell culture medium;b) an affinity chromatography step;c) a second chromatography step;d) a low pH viral inactivation step; wherein the pH of the elution pool of the second chromatography step is adjusted to a pH of approximately 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0, incubate for approximately 30-90 min or approximately 60 min, and then adjusted to a pH of 5.5 - 8.0; ande) additional process steps.

23. The method of any one of claims 13-21 , which comprises the following steps with optional filtration step or steps before and / or after each chromatography step:a) clarification of the cultured cell culture medium;b) an affinity chromatography step;c) a second chromatography step;d) a third chromatography step;e) a low pH viral inactivation step; wherein the pH of the elution pool of the third chromatography step is adjusted to a pH of approximately 3.6, incubate for approximately 60 min at room temperature, and is adjusted to a pH of 5.5 - 8.0; andf) additional process steps.

24. The method of any one of claims 13-21 , which comprises the following steps with optional filtration step or steps before and / or after each chromatography step:a) clarification of the cultured cell culture medium;46MEl\60901856.vlAttorney Docket No.: 143302-00520b) a Protein L affinity chromatography step;c) an anion exchange chromatography step carried out in a flow-through mode;d) a cation exchange chromatography step;e) a low pH viral inactivation step; wherein the pH of the elution pool of the cation exchange chromatography step is adjusted to a pH of approximately 3.6, incubate for approximately 60 min at room temperature, and is adjusted to a pH of 5.5 - 8.0 or optionally approximately 7.5; andf) additional process steps.

25. The method of any one of claims 11-15, further comprising a viral-inactivation step;wherein the viral-inactivation step is not a low-pH viral-inactivation step; and wherein the viral-inactivation step optionally uses an organic-solvent or UV to inactivate potential viral particles in a product pool.

26. A pharmaceutical composition which comprises the chimeric molecule purified by the method of any one of claims 13-24 as its active ingredient, wherein the pharmaceutical composition is used to treat a patient with proliferative retinopathy, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

27. The pharmaceutical composition of claim 26, further comprising a second active ingredient at a concentration of 0.5 mg / ml or higher, a concentration of 1.0 mg / ml or higher, or a concentration of 1.5 mg / ml or higher; wherein the second active ingredient comprises a chimeric molecule, which comprises two identical light chains and two identical heavy chain-peptide fusion polypeptide chains; andwherein said light chain comprises the amino acid sequence of SEQ ID NO: 26, and said heavy chain-peptide fusion polypeptide chain comprises an amino acid sequence selected from any one of SEQ ID NOs: 28, 29, 30, 32, 33, 34, 35, and 36.

28. The pharmaceutical composition of claim 26 or 27, further comprising a47MEl\60901856.vlAttorney Docket No.: 143302-00520second active ingredient at a concentration of 15.0 mg / ml or lower, concentration of 10.0 mg / ml or lower, or a concentration of 6.0 mg / ml or lower; wherein the second active ingredient comprises a chimeric molecule, which comprises two identical light chains and two identical heavy chain- peptide fusion polypeptide chains; and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 26, and the heavy chain-peptide fusion polypeptide chain comprises an amino acid sequence selected from any one of SEQ ID NOs: 28, 29, 30, 32, 33, 34, 35, and 36.

29. The pharmaceutical composition of claim 26, further comprising a second active ingredient at a concentration of 0.5 mg / ml or higher, a concentration of 1.0 mg / ml or higher, or a concentration of 1.5 mg / ml or higher;wherein the second active ingredient comprises a chimeric molecule, which comprises two identical polypeptide chains which comprise an amino acid sequence selected from any one of SEQ ID NOs: 22-25.

30. The pharmaceutical composition of claim 26, further comprising a second active ingredient at a concentration of 15.0 mg / ml or lower, concentration of 10.0 mg / ml or lower, or a concentration of 6.0 mg / ml or lower;wherein the second active ingredient comprises a chimeric molecule, which comprises two identical polypeptide chains which comprise an amino acid sequence selected from any one of SEQ ID NOs: 22 - 25.48MEl\60901856.vl